Literature DB >> 31915083

Pathogens causing central-line-associated bloodstream infections in acute-care hospitals-United States, 2011-2017.

Shannon A Novosad1, Lucy Fike1, Margaret A Dudeck1, Katherine Allen-Bridson1, Jonathan R Edwards1, Chris Edens2, Ronda Sinkowitz-Cochran1, Krista Powell1, David Kuhar1.   

Abstract

OBJECTIVE: To describe pathogen distribution and rates for central-line-associated bloodstream infections (CLABSIs) from different acute-care locations during 2011-2017 to inform prevention efforts.
METHODS: CLABSI data from the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) were analyzed. Percentages and pooled mean incidence density rates were calculated for a variety of pathogens and stratified by acute-care location groups (adult intensive care units [ICUs], pediatric ICUs [PICUs], adult wards, pediatric wards, and oncology wards).
RESULTS: From 2011 to 2017, 136,264 CLABSIs were reported to the NHSN by adult and pediatric acute-care locations; adult ICUs and wards reported the most CLABSIs: 59,461 (44%) and 40,763 (30%), respectively. In 2017, the most common pathogens were Candida spp/yeast in adult ICUs (27%) and Enterobacteriaceae in adult wards, pediatric wards, oncology wards, and PICUs (23%-31%). Most pathogen-specific CLABSI rates decreased over time, excepting Candida spp/yeast in adult ICUs and Enterobacteriaceae in oncology wards, which increased, and Staphylococcus aureus rates in pediatric locations, which did not change.
CONCLUSIONS: The pathogens associated with CLABSIs differ across acute-care location groups. Learning how pathogen-targeted prevention efforts could augment current prevention strategies, such as strategies aimed at preventing Candida spp/yeast and Enterobacteriaceae CLABSIs, might further reduce national rates.

Entities:  

Mesh:

Year:  2020        PMID: 31915083     DOI: 10.1017/ice.2019.303

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  8 in total

1.  Treatment duration for central line-associated infection caused by Enterococcus spp.: a retrospective evaluation of a multicenter cohort.

Authors:  Elena Rosselli Del Turco; Zeno Pasquini; Kristian Scolz; Alberto Amedeo; Giacomo Beci; Maddalena Giglia; Linda Bussini; Sulamita Carvalho-Brugger; Laura Gutiérrez; Sara Tedeschi; Mercè Garcia; Simone Ambretti; Juan M Pericàs; Maddalena Giannella; Pierluigi Viale; Michele Bartoletti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-08-01       Impact factor: 5.103

2.  Early Oral Antibiotic Switch for Staphylococcus aureus Bacteremia: Many Are Called, but Few Are Chosen.

Authors:  Thomas L Holland
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

3.  Chemokine CCL28 Is a Potent Therapeutic Agent for Oropharyngeal Candidiasis.

Authors:  Jie He; Monica A Thomas; Jaime de Anda; Michelle W Lee; Emma Van Why; Pippa Simpson; Gerard C L Wong; Mitchell H Grayson; Brian F Volkman; Anna R Huppler
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

Review 4.  The Changing Face of the Family Enterobacteriaceae (Order: "Enterobacterales"): New Members, Taxonomic Issues, Geographic Expansion, and New Diseases and Disease Syndromes.

Authors:  J Michael Janda; Sharon L Abbott
Journal:  Clin Microbiol Rev       Date:  2021-02-24       Impact factor: 26.132

5.  Local signs at insertion site and catheter-related bloodstream infections: an observational post hoc analysis using individual data of four RCTs.

Authors:  Niccolò Buetti; Stéphane Ruckly; Jean-Christophe Lucet; Lila Bouadma; Maité Garrouste-Orgeas; Carole Schwebel; Olivier Mimoz; Bertrand Souweine; Jean-François Timsit
Journal:  Crit Care       Date:  2020-12-14       Impact factor: 9.097

6.  Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey.

Authors:  Kai-Manuel Adam; Michael Osthoff; Frédéric Lamoth; Anna Conen; Véronique Erard; Katia Boggian; Peter W Schreiber; Stefan Zimmerli; Pierre-Yves Bochud; Dionysios Neofytos; Mapi Fleury; Hans Fankhauser; Daniel Goldenberger; Konrad Mühlethaler; Arnaud Riat; Reinhard Zbinden; Andreas Kronenberg; Chantal Quiblier; Oscar Marchetti; Nina Khanna
Journal:  Open Forum Infect Dis       Date:  2021-09-17       Impact factor: 3.835

Review 7.  Antifungal lock therapy: an eternal promise or an effective alternative therapeutic approach?

Authors:  R Kovács; L Majoros
Journal:  Lett Appl Microbiol       Date:  2022-01-30       Impact factor: 2.813

8.  Mode and dynamics of vanA-type vancomycin resistance dissemination in Dutch hospitals.

Authors:  Sergio Arredondo-Alonso; Janetta Top; Jukka Corander; Rob J L Willems; Anita C Schürch
Journal:  Genome Med       Date:  2021-01-20       Impact factor: 11.117

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.